Immunomodulation by anticancer cell cycle inhibitors

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996 · see citing works

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · see citing works

Cellular Senescence: Defining a Path Forward

Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225 · see citing works

Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA

Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. A. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,000 · see citing works

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · see citing works

Innate or adaptive immunity? The example of natural killer cells

Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824 · see citing works

Dendritic cells in cancer immunology and immunotherapy

Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,594 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence

Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · see citing works

Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals

Polyák, K., Lee, M.-H., Erdjument‐Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118 · see citing works

The Immunological Genome Project: networks of gene expression in immune cells

The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864 · see citing works

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · see citing works

Chemokine signaling via the CXCR2 receptor reinforces senescence

Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801 · see citing works

Cyclin-dependent kinases

Malumbres, M. (2014) · Genome biology · doi:10.1186/gb4184 · Cited by 1,683 · see citing works

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development

Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621 · see citing works

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · see citing works

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429 · see citing works

Autophagy maintains stemness by preventing senescence

García-Prat, L., Martínez-Vicente, M., Perdiguero, E., Ortet, L., Rodríguez-Ubreva, J., Rebollo, E., Ruiz-Bonilla, V., Gutarra, S., Ballestar, E., Serrano, A. L., et al. (2016) · Nature · doi:10.1038/nature16187 · Cited by 1,355 · see citing works

Cellular senescence promotes adverse effects of chemotherapy and cancer relapse

Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338 · see citing works

Type I interferons in anticancer immunity

Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305 · see citing works

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,303 · see citing works

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264 · see citing works

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · see citing works

DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.

Di Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215 · see citing works

Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence

Glück, S., Guey, B., Gulen, M. F., Wolter, K., Kang, T.-W., Schmacke, N. A., Bridgeman, A., Rehwinkel, J., Zender, L., & Ablasser, A. (2017) · Nature Cell Biology · doi:10.1038/ncb3586 · Cited by 1,196 · see citing works

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

Laberge, R.-M., Sun, Y., Orjalo, A. V., Patil, C. K., Freund, A., Zhou, L., Curran, S. C., Davalos, A. R., Wilson-Edell, K. A., Liu, S., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3195 · Cited by 1,160 · see citing works

Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors

Zhu, Y., Tchkonia, T., Fuhrmann‐Stroissnigg, H., Dai, H. M., Ling, Y. Y., Stout, M. B., Pirtskhalava, T., Giorgadze, N., Johnson, K. O., Giles, C. B., et al. (2016) · Aging Cell · doi:10.1111/acel.12445 · Cited by 1,148 · see citing works

Treating cancer with selective CDK4/6 inhibitors

O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137 · see citing works

Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control

van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092 · see citing works

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057 · see citing works

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013 · see citing works

Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts

Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008 · see citing works

A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B

King, R. W., Peters, J., Tugendreich, S., Rolfe, M., Hieter, P., & Kirschner, M. W. (1995) · Cell · doi:10.1016/0092-8674(95)90338-0 · Cited by 956 · see citing works

p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5

Tsai, L., Delalle, I., Caviness, V. S., Chae, T. H., & Harlow, E. (1994) · Nature · doi:10.1038/371419a0 · Cited by 923 · see citing works

Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.Preprint

Lee, M., Reynisdóttir, I., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.6.639 · Cited by 889 · see citing works

Unmasking senescence: context-dependent effects of SASP in cancer

Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863 · see citing works

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848 · see citing works

Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles

Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842 · see citing works

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793 · see citing works

The broken cycle: E2F dysfunction in cancer

Kent, L. N., & Leone, G. W. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 786 · see citing works

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · see citing works

Non-Cell-Autonomous Tumor Suppression by p53

Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · see citing works

Control of Metastasis by NK Cells

López‐Soto, A., Gonzalez, S. R., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 730 · see citing works

Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways

Alarcón, C., Zaromytidou, A.-I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A. N., Manova-Todorova, K., Macias, M. J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.035 · Cited by 719 · see citing works

Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.Preprint

Guan, K., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 707 · see citing works

Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia

Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700 · see citing works

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells

De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687 · see citing works

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684 · see citing works

Impact of oncogenic pathways on evasion of antitumour immune responses

Spranger, S., & Gajewski, T. F. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.117 · Cited by 663 · see citing works

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

O’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650 · see citing works

Mouse development and cell proliferation in the absence of D-cyclins

Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647 · see citing works

CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages

Kitamura, T., Qian, B., Soong, D. Y. H., Cassetta, L., Noy, R., Sugano, G., Kato, Y., Li, J., & Pollard, J. W. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141836 · Cited by 644 · see citing works

Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family

Koff, A., Cross, F., Fisher, A. L., Schumacher, J. M., Guellec, K. L., Philippe, M., & Roberts, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90044-y · Cited by 642 · see citing works

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577 · see citing works

The hallmarks of successful anticancer immunotherapy

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575 · see citing works

Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment

Zhong, Z., Sánchez‐López, E., & Karin, M. (2016) · Cell · doi:10.1016/j.cell.2016.05.051 · Cited by 574 · see citing works

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543 · see citing works

Linking cellular stress responses to systemic homeostasis

Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 529 · see citing works

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517 · see citing works

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513 · see citing works

NF-κB and the Transcriptional Control of Inflammation

Mitchell, J. P., & Carmody, R. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.007 · Cited by 503 · see citing works

Untitled work

(1995) · PubMed · Cited by 496 · see citing works

Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis

Ruhland, M. K., Loza, A. J., Capietto, A.-H., Luo, X., Knolhoff, B. L., Flanagan, K. C., Belt, B. A., Alspach, E., Leahy, K., Luo, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11762 · Cited by 496 · see citing works

Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes

Fang, F., & Newport, J. W. (1991) · Cell · doi:10.1016/0092-8674(91)90117-h · Cited by 483 · see citing works

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469 · see citing works

Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase

Tsai, L., Harlow, E., & Meyerson, M. M. (1991) · Nature · doi:10.1038/353174a0 · Cited by 461 · see citing works

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444 · see citing works

Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

Toso, A., Revandkar, A., Di Mitri, D., Guccini, I., Proietti, M., Sarti, M., Pinton, S., Zhang, J., Kalathur, M., Civenni, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.044 · Cited by 418 · see citing works

NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science · doi:10.1126/science.aas9090 · Cited by 415 · see citing works

p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells

Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414 · see citing works

CDK inhibitors p18INK4c and p27Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesisPreprint

Franklin, D. S., Godfrey, V., Lee, H., Kovalev, G. I., Schoonhoven, R., Chen-Kiang, S., Su, L., & Xiong, Y. (1998) · Genes & Development · doi:10.1101/gad.12.18.2899 · Cited by 409 · see citing works

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

Condorelli, R., Spring, L. M., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J. S., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 398 · see citing works

Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer

Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388 · see citing works

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378 · see citing works

The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival

Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347 · see citing works

A versatile drug delivery system targeting senescent cells

Muñoz‐Espín, D., Rovira, M., Galiana, I., Giménez, C., Lozano‐Torres, B., Paez‐Ribes, M., Llanos, S., Chaib, S., Muñoz‐Martín, M., Ucero, A. C., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809355 · Cited by 339 · see citing works

Requirement for cyclin D3 in lymphocyte development and T cell leukemias

Sicińska, E., Aifantis, I., Cam, L. L., Swat, W., Borowski, C., Yu, Q., Ferrando, A. A., Levin, S. D., Geng, Y., von Boehmer, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00301-5 · Cited by 338 · see citing works

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313 · see citing works

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · see citing works

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299 · see citing works

CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response

Bancerek, J., Poss, Z. C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T., Mikulic, I., Dölken, L., Strobl, B., Müller, M., Taatjes, D. J., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.017 · Cited by 297 · see citing works

Chemotherapy induced DNA damage response: Convergence of drugs and pathways

Woods, D., & Turchi, J. J. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23761 · Cited by 296 · see citing works

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers

Vijayaraghavan, S., Karakaş, C., Doostan, I., Chen, X., Bui, T. N., Yi, M., Raghavendra, A. S., Zhao, Y., Bashour, S. I., Ibrahim, N. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15916 · Cited by 294 · see citing works

The autophagic network and cancer

Rybstein, M. D., Pedro, J. M. B., Kroemer, G., & Galluzzi, L. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0042-2 · Cited by 287 · see citing works

Cell-Cycle Proteins Control Production of Neutrophil Extracellular Traps

Amulic, B., Knackstedt, S. L., Abed, U. A., Deigendesch, N., Harbort, C. J., Caffrey, B. E., Brinkmann, V., Heppner, F. L., Hinds, P. W., & Zychlinsky, A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.10.013 · Cited by 269 · see citing works

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 261 · see citing works

CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.

Bates, S., Bonetta, L. P., MacAllan, D., Parry, D., Holder, A. A., Dickson, C., & Peters, G. (1994) · PubMed · Cited by 260 · see citing works

Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer

Formenti, S. C., Lee, P. P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L. H., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 258 · see citing works

Macrophages

Guerriero, J. L. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.07.001 · Cited by 245 · see citing works

Oncogene-induced senescence and tumour control in complex biological systems

Galluzzi, L., & Vitale, I. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0102-y · Cited by 244 · see citing works

p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes

Boussiotis, V. A., Freeman, G. J., Taylor, P. A., Berezovskaya, A., Grass, I., Blazar, B. R., & Nadler, L. M. (2000) · Nature Medicine · doi:10.1038/73144 · Cited by 231 · see citing works

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6

Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225 · see citing works

Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2

Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3211 · Cited by 221 · see citing works

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.003 · Cited by 218 · see citing works

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

McCartney, A., Migliaccio, I., Bonechi, M., Biagioni, C., Romagnoli, D., Luca, F. D., Galardi, F., Risi, E., Santo, I. D., Benelli, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00666 · Cited by 188 · see citing works

Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles

Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183 · see citing works

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

Michaloglou, C., Crafter, C., Siersbæk, R., Delpuech, O., Curwen, J., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 180 · see citing works

The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells

Obata, Y., Furusawa, Y., Endo, T. A., Sharif, J., Takahashi, D., Atarashi, K., Nakayama, M., Onawa, S., Fujimura, Y., Takahashi, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2886 · Cited by 175 · see citing works

NFATc2-Mediated Repression of Cyclin-Dependent Kinase 4 Expression

Baksh, S., Widlund, H. R., Frazer‐Abel, A. A., Du, J., Fosmire, S. P., Fisher, D. E., DeCaprio, J. A., Modiano, J. F., & Burakoff, S. J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00701-3 · Cited by 172 · see citing works

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1

Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms13923 · Cited by 161 · see citing works

Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4/6

Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153 · see citing works

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

Cornell, L., Wander, S. A., Visal, T. H., Wagle, N., & Shapiro, G. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.023 · Cited by 139 · see citing works

Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance

Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138 · see citing works

Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development

Solvason, N. W., Wu, W. W., Parry, D., Mahony, D., Lam, E. W. ‐., Glassford, J., Klaus, G. G. B., Siciński, P., Weinberg, R. A., Liu, Y.-J., et al. (2000) · International Immunology · doi:10.1093/intimm/12.5.631 · Cited by 135 · see citing works

A unique function for cyclin D3 in early B cell development

Cooper, A. B., Sawai, C. M., Sicińska, E., Powers, S. E., Siciński, P., Clark, M. R., & Aifantis, I. (2006) · Nature Immunology · doi:10.1038/ni1324 · Cited by 126 · see citing works

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124 · see citing works

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

Vilgelm, A. E., Saleh, N., Shattuck-Brandt, R. L., Riemenschneider, K., Slesur, L., Chen, S., Johnson, C. A., Yang, J., Blevins, A., Yan, C. W., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7171 · Cited by 123 · see citing works

CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells.

Tourigny, M., Ursini-Siegel, J., Lee, H., Toellner, K., Cunningham, A., Franklin, D., Ely, S., Chen, M., Qin, X.-F. F., Xiong, Y., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00364-3 · Cited by 121 · see citing works

A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis

Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 116 · see citing works

Foxp3 Protein Stability Is Regulated by Cyclin-dependent Kinase 2*

Morawski, P. A., Mehra, P., Chen, C., Bhatti, T. R., & Wells, A. D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467704 · Cited by 114 · see citing works

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111 · see citing works

Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth

Guan, X., LaPak, K. M., Hennessey, R. C., Yu, C. Y., Shakya, R., Zhang, J., & Burd, C. E. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0319 · Cited by 104 · see citing works

Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies

Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 98 · see citing works

Lysosomal trapping of palbociclib and its functional implications

Llanos, S., Megias, D., Blanco-Aparicio, C., Hernández-Encinas, E., Rovira, M., Pietrocola, F., & Serrano, M. (2019) · Oncogene · doi:10.1038/s41388-019-0695-8 · Cited by 96 · see citing works

Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment

Vilgelm, A. E., Johnson, C. A., Prasad, N., Yang, J., Chen, S.-C., Ayers, G. D., Pawlikowski, J. S., Raman, D., Sosman, J. A., Kelley, M., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv406 · Cited by 95 · see citing works

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy

Rolfes, V., Idel, C., Pries, R., Plötze‐Martin, K., Habermann, J. K., Gemoll, T., Bohnet, S., Latz, E., Ribbat‐Idel, J., Franklin, B. S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25446 · Cited by 94 · see citing works

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy

Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94 · see citing works

ATRX is a regulator of therapy induced senescence in human cells

Kovatcheva, M., Liao, W., Klein, M. E., Robine, N., Geiger, H., Crago, A. M., Dickson, M. A., Tap, W. D., Singer, S., & Koff, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00540-5 · Cited by 89 · see citing works

Modeling Tumor Immunology and Immunotherapy in Mice

Buqué, A., & Galluzzi, L. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.07.003 · Cited by 88 · see citing works

Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules

Dannappel, M., Sooraj, D., Loh, J. J., & Firestein, R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00171 · Cited by 88 · see citing works

CDK6 kinase activity is required for thymocyte development

Hu, M. G., Deshpande, A., Schlichting, N., Hinds, E. A., Mao, C., Dose, M., Hu, G., Etten, R. A. V., Gounari, F., & Hinds, P. W. (2011) · Blood · doi:10.1182/blood-2010-08-300517 · Cited by 84 · see citing works

CDK5: A Unique CDK and Its Multiple Roles in the Nervous System

Cortés, N., Guzmán‐Martínez, L., Andrade, V., González, A., & Maccioni, R. B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180792 · Cited by 82 · see citing works

Cyclin D3 Is Selectively Required for Proliferative Expansion of Germinal Center B Cells

Cato, M. H., Chintalapati, S. K., Yau, I. W., Omori, S. A., & Rickert, R. C. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00650-10 · Cited by 80 · see citing works

Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer

Ishak, C. A., Classon, M., & Carvalho, D. D. D. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.008 · Cited by 79 · see citing works

New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation

Wells, A. D., & Morawski, P. A. (2014) · Nature reviews. Immunology · doi:10.1038/nri3625 · Cited by 77 · see citing works

Cyclin-Dependent Kinase 2 Controls Peripheral Immune Tolerance

Chunder, N., Wang, L., Chen, C., Hancock, W. W., & Wells, A. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202313 · Cited by 75 · see citing works

Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis

Pareek, T. K., Lam, E., Zheng, X., Askew, D., Kulkarni, A. B., Chance, M. R., Huang, A. Y.-C., Cooke, K. R., & Letterio, J. J. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100876 · Cited by 73 · see citing works

Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells

Johannessen, L. H., Sundberg, T. B., O'Connell, D. J., Kolde, R., Berstler, J., Billings, K., Khor, B., Seashore-Ludlow, B. A., Fassl, A., Russell, C. N., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2458 · Cited by 73 · see citing works

CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation

Lopez-Mejia, I. C., Lagarrigue, S., Giralt, A., Martinez-Carreres, L., Zanou, N., Denechaud, P.-D., Castillo-Armengol, J., Chavey, C., Orpinell, M., Delacuisine, B., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.034 · Cited by 71 · see citing works

Immunomodulatory Roles of Cell Cycle Regulators

Laphanuwat, P., & Jirawatnotai, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00023 · Cited by 71 · see citing works

Cloning and characterization of murine p16INK4a and p15INK4b genes.

Quelle, D. E., Ashmun, R. A., Hannon, G. J., Rehberger, P. A., Trono, D., Richter, K. H., Walker, C., Beach, D., Sherr, C. J., & Serrano, M. (1995) · PubMed · Cited by 69 · see citing works

Characterization of cytokine differential induction of STAT complexes in primary human T and NK cells

Yu, C., Young, H. A., & Ortaldo, J. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.2.245 · Cited by 69 · see citing works

A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence

Acevedo, M., Vernier, M., Mignacca, L., Lessard, F., Huot, G., Moiseeva, O. V., Bourdeau, V., & Ferbeyre, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2347 · Cited by 68 · see citing works

Cyclin-dependent kinase activity is required for type I interferon production

Cingöz, O., & Goff, S. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720431115 · Cited by 68 · see citing works

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK 4/6‐independent manner

Hsieh, F., Chen, Y., Hung, M., Chu, P., Tsai, M., Chen, L., Hsiao, Y., Shih, C., Chang, M.-J., Chao, T., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12072 · Cited by 63 · see citing works

Requirement for cyclin D3 in germinal center formation and function

Peled, J. U., Yu, J. J., Jeganathan, V., Bi, E., Ding, B. B., Krupski, M., Shaknovich, R., Siciński, P., Diamond, B., Scharff, M. D., et al. (2010) · Cell Research · doi:10.1038/cr.2010.55 · Cited by 61 · see citing works

To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity

Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 59 · see citing works

Molecular Cloning, Expression Pattern, and Chromosomal Localization of Human CDKN2D/INK4d,an Inhibitor of Cyclin D-Dependent Kinases

Okuda, T., Hirai, H., Valentine, V. A., Shurtleff, S. A., Kidd, V. J., Lahti, J. M., Sherr, C. J., & Downing, J. R. (1995) · Genomics · doi:10.1006/geno.1995.9957 · Cited by 57 · see citing works

Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases

Guo, Z., Wang, G., Lv, Y., Wan, Y. Y., & Zheng, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01988 · Cited by 54 · see citing works

NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses

Witalisz-Siepracka, A., Gotthardt, D., Prchal-Murphy, M., Didara, Z., Menzl, I., Prinz, D., Edlinger, L., Putz, E. M., & Sexl, V. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0183 · Cited by 47 · see citing works

CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

Martínez-Carreres, L., Puyal, J., Leal-Esteban, L. C., Orpinell, M., Castillo‐Armengol, J., Giralt, A., Dergai, O., Moret, C., Barquissau, V., Nasrallah, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0708 · Cited by 47 · see citing works

SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors

Yoshida, A., Bu, Y., Qie, S., Wrangle, J. M., Camp, E. R., Hazard, E. S., Hardiman, G., de Leeuw, R., Knudsen, K. E., & Diehl, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aax6352 · Cited by 46 · see citing works

Essential role for cyclin D3 in granulocyte colony-stimulating factor-driven expansion of neutrophil granulocytes

Sicinska, E., Lee, Y.-M., Gits, J., Shigematsu, H., Yu, Q., Rebel, V. I., Geng, Y., Marshall, C. J., Akashi, K., Dorfman, D. M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00800-06 · Cited by 45 · see citing works

Interplay between dendritic cells and cancer cells

Martínek, J., Wu, T.-C., Cadena, D., Banchereau, J., & Palucka, K. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.07.008 · Cited by 44 · see citing works

Cyclin-dependent kinase 5 represses Foxp3 gene expression and Treg development through specific phosphorylation of Stat3 at Serine 727

Lam, E., Choi, S. H., Pareek, T. K., Kim, B.-G., & Letterio, J. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.06.015 · Cited by 32 · see citing works

CDK-Mediated Regulation of Cell Functions via c-Jun Phosphorylation and AP-1 Activation

Bush, T. J. V., & Bishop, G. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019468 · Cited by 32 · see citing works

The Cyclin-Dependent Kinase Inhibitor p27kip1 Is Required for Transplantation Tolerance Induced by Costimulatory Blockade

Rowell, E. A., Wang, L., Hancock, W. W., & Wells, A. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5169 · Cited by 31 · see citing works

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy

Marie, P. K., Lam, M. S., Sorokin, A. V., Overman, M. J., Kopetz, S., & Menter, D. G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00107 · Cited by 29 · see citing works

SASP-Dependent Interactions between Senescent Cells and Platelets Modulate Migration and Invasion of Cancer Cells

Valenzuela, C. A., Quintanilla, R., Olate‐Briones, A., Venturini, W., Mancilla, D., Cayo, Á., Moore‐Carrasco, R., & Brown, N. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215292 · Cited by 27 · see citing works

Cdk5 controls IL-2 gene expression via repression of the mSin3a-HDAC complex

Lam, E., Pareek, T. K., & Letterio, J. J. (2015) · Cell Cycle · doi:10.4161/15384101.2014.987621 · Cited by 23 · see citing works

Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice

Askew, D., Pareek, T. K., Eid, S. K., Ganguly, S., Tyler, M., Huang, A. Y.-C., Letterio, J. J., & Cooke, K. R. (2016) · Blood · doi:10.1182/blood-2016-05-702738 · Cited by 20 · see citing works

First Insight into the Kinome of Human Regulatory T Cells

König, S., Probst‐Kepper, M., Reinl, T., Jeron, A., Huehn, J., Schraven, B. L., & Jänsch, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040896 · Cited by 16 · see citing works

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

Bonapace, L., Coissieux, M., Wyckoff, J. B., Mertz, K. D., Varga, Z., Junt, T., & Bentires‐Alj, M. (2014) · Zurich Open Repository and Archive (University of Zurich) · doi:10.1038/nature13862 · Cited by 15 · see citing works

T‐cell intrinsic and extrinsic mechanisms of p27Kip1 in the regulation of CD8 T‐cell memory

Jatzek, A., Tejera, M. M., Plisch, E. H., Fero, M. L., & Suresh, M. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.71 · Cited by 13 · see citing works

Regulation of T Cell Differentiation and Alloimmunity by the Cyclin-Dependent Kinase Inhibitor p18ink4c

Rowell, E. A., Wang, L., Chunder, N., Hancock, W. W., & Wells, A. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091587 · Cited by 10 · see citing works

Immunogenic cell stress and death

Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353 · see citing works

Targeting immunogenic cell stress and death for cancer therapy

Galluzzi, L., Guilbaud, E., Schmidt, D. R., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 595 · see citing works

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Yamaguchi, H., Hsu, J.-M., Yang, W., & Hung, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 507 · see citing works

Emerging evidence for adapting radiotherapy to immunotherapy

Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 381 · see citing works

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 215 · see citing works

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212 · see citing works

Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162 · see citing works

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: an update review

Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131 · see citing works

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108 · see citing works

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

Slamon, D. J., Fasching, P. A., Hurvitz, S. A., Chia, S., Crown, J. P., Martín, M., Barrios, C. H., Bardia, A., Im, S., Yardley, D. A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231178125 · Cited by 105 · see citing works

Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors

Uzhachenko, R. V., Bharti, V., Ouyang, Z., Blevins, A., Mont, S., Saleh, N., Lawrence, H. A., Shen, C., Chen, S., Ayers, G. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108944 · Cited by 108 · see citing works

Autophagy in the cancer-immunity dialogue

Yamazaki, T., Pedro, J. M. B., Galluzzi, L., Kroemer, G., & Pietrocola, F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.003 · Cited by 78 · see citing works

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization

Yang, Y., Luo, J., Chen, X., Yang, Z., Mei, X., Ma, J., Zhang, Z., Guo, X., & Yu, X. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01693-w · Cited by 74 · see citing works

Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer

Petroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen‐Kiang, S., Formenti, S. C., & Galluzzi, L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3871 · Cited by 70 · see citing works

Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma

Yin, X., Wang, Z., Wang, J., Xu, Y., Kong, W., & Zhang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1933332 · Cited by 53 · see citing works

Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?

Riess, C., Irmscher, N., Salewski, I., Strüder, D., Classen, C.-F., Große-Thie, C., Junghanß, C., & Maletzki, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09940-4 · Cited by 47 · see citing works

Targeting cyclin‐dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies

Yousuf, M., Shamsi, A., Queen, A., Shahbaaz, M., Κhan, P., Hussain, A., Alajmi, M. F., Haque, Q. M. R., & Hassan, M. I. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29921 · Cited by 47 · see citing works

Circular RNAs in cell cycle regulation: Mechanisms to clinical significance

Xiao, W., Li, J., Hu, J., Wang, L., Huang, J. R., Sethi, G., & Ma, Z. (2021) · Cell Proliferation · doi:10.1111/cpr.13143 · Cited by 47 · see citing works

Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy

Petroni, G., Pillozzi, S., & Antonuzzo, L. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3325 · Cited by 46 · see citing works

Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms

Zhao, H., Han, B., Li, X., Sun, C., Zhai, Y., Li, M., Jiang, M., Zhang, W., Liang, Y., & Kai, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.872085 · Cited by 40 · see citing works

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 41 · see citing works

Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha

Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Han, Y., Qian, G., Nicol, P. B., Zeng, Z., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0244 · Cited by 35 · see citing works

Immunomodulatory effects of CDK4/6 inhibitors

Zhang, S., Xu, Q., Sun, W., Zhou, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188912 · Cited by 34 · see citing works

Function of p21 and its therapeutic effects in esophageal cancer (Review)

Wang, L., Han, H., Dong, L., Wang, Z., & Qin, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.12397 · Cited by 34 · see citing works

Targeting CDK7 in oncology: The avenue forward

Li, Z., Liu, G., Gao, Y., & Zhao, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108229 · Cited by 34 · see citing works

IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages

Petroni, G., Galassi, C., Gouin, K. H., Chen, H., Buqué, A., Bloy, N., Yamazaki, T., Sato, A., Beltrán‐Visiedo, M., Campia, G., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01007-z · Cited by 33 · see citing works

Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy

Zhang, B., Zou, J., Zhang, Q., Wang, Z., Wang, N., He, S., Zhao, Y., & Naman, C. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052408 · Cited by 31 · see citing works

Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

Fucikova, J. P., Palová-Jelínková, L., Klapp, V., Holíček, P., Láníčková, T., Kašíková, L., Drozenová, J., Cibula, D., Álvarez-Abril, B., García-Martínez, E., et al. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.010 · Cited by 31 · see citing works

Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents

Petroni, G., & Galluzzi, L. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1889101 · Cited by 29 · see citing works

Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug

Li, H., Hu, P., Zou, Y., Yuan, L., Xu, Y., Zhang, X., Luo, X., & Zhang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1071415 · Cited by 27 · see citing works

Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells

Favaretto, G., Rossi, M. N., Cuollo, L., Laffranchi, M., Cervelli, M., Soriani, A., Sozzani, S., Santoni, A., & Antonangeli, F. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03695-5 · Cited by 24 · see citing works

Pan-inhibition of the three H2S synthesizing enzymes restrains tumor progression and immunosuppression in breast cancer

Dawoud, A., Youness, R. A., Nafea, H., Manie, T., Bourquin, C., Szabó, C., Abdel-Kader, R. M., & Gad, M. Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03317-1 · Cited by 23 · see citing works

Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors

Klapp, V., Buqué, A., Bloy, N., Sato, A., Yamazaki, T., Zhou, X. K., Formenti, S. C., Galluzzi, L., & Petroni, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03964-4 · Cited by 23 · see citing works

The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

Schober, S. J., Schoening, C., Eck, J., Middendorf, C., Lutsch, J., Knoch, P., von Ofen, A. J., Gassmann, H., Thiede, M., Hauer, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1961 · Cited by 23 · see citing works

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors

Salewski, I., Henne, J., Engster, L., Krone, P., Schneider, B., Redwanz, C., Lemcke, H., Henze, L., Junghanß, C., & Maletzki, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2094583 · Cited by 22 · see citing works

CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules

Wu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03400-z · Cited by 21 · see citing works

Molecular Mechanism of Tanshinone against Prostate Cancer

Li, W., Huang, T., Xu, S., Che, B., Yu, Y., Zhang, W., & Tang, K. (2022) · Molecules · doi:10.3390/molecules27175594 · Cited by 21 · see citing works

Tumor immune checkpoints and their associated inhibitors

Gao, Z., Ling, X., Shi, C., Wang, Y., & Lin, A. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200195 · Cited by 20 · see citing works

Cell cycle inhibitors activate the hypoxia-induced DDX41/STING pathway to mediate antitumor immune response in liver cancer

Wong, P. Y., Chan, C. Y. K., Xue, H. D. G., Goh, C. C., Cheu, J. W., Tse, A. P., Zhang, M. S., Zhang, Y., & Wong, C. C. (2024) · JCI Insight · doi:10.1172/jci.insight.170532 · Cited by 20 · see citing works

Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome

Tovar, I., Guerrero, R., López‐Peñalver, J. J., Expósito, J., & de Almodóvar, J. M. R. (2020) · Cells · doi:10.3390/cells9092015 · Cited by 18 · see citing works

Stable germline transgenesis using the Minos Tc1/ mariner element in the sea urchin Lytechinus pictus

Jackson, E. W., Romero, E., Kling, S., Lee, Y., Tjeerdema, E., & Hamdoun, A. M. (2024) · Development · doi:10.1242/dev.202991 · Cited by 17 · see citing works

C4orf19 inhibits colorectal cancer cell proliferation by competitively binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis

Huang, S., Li, J., Wu, S., Zheng, Z., Wang, C., Li, H., Zhao, L., Zhang, X., Huang, H., Huang, C., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02656-z · Cited by 16 · see citing works

MicroRNA‑186‑3p attenuates tumorigenesis of cervical cancer by targeting MCM2

Lu, X., Song, X., Hao, X., Liu, X., Zhang, X., Yuan, N., Ma, H., & Zhang, Z. (2021) · Oncology Letters · doi:10.3892/ol.2021.12800 · Cited by 16 · see citing works

An Overview on the Anticancer Potential of Punarnavine: Prediction of Drug-Like Properties

Ahmad, I. I., Khan, H. Z., Amin, M. U., Khalid, S., Behl, T., & Rahman, N. U. (2021) · ONCOLOGIE · doi:10.32604/oncologie.2021.018296 · Cited by 16 · see citing works

ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma

Zhang, S., Xu, L., Feng, J., Tan, D., Zhu, Y., Hou, J., Li, W., Lv, K., Wang, W., Jiang, L., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.842351 · Cited by 16 · see citing works

Particle radiotherapy and molecular therapies: mechanisms and strategies towards clinical applications

Helm, A., Fournier, C., & Durante, M. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.2 · Cited by 15 · see citing works

MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma

Fang, J., Zhen, J., Gong, Y., Ke, Y., Fu, B., Jiang, Y., Xie, J., Liu, Y., Ding, Y., Huang, D., et al. (2022) · Aging · doi:10.18632/aging.204280 · Cited by 14 · see citing works

Immunology of Cell Death in Cancer Immunotherapy

Galluzzi, L., & Garg, A. D. (2021) · Cells · doi:10.3390/cells10051208 · Cited by 15 · see citing works

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma

Zhang, W., Shang, X., Yang, F., Han, W., Xia, H., Liu, G., Liu, Y., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.867788 · Cited by 15 · see citing works

Cell Cycle-Related Clinical Applications

Khan, M. G. M., & Wang, Y. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2736-5_3 · Cited by 14 · see citing works

Cuproptosis Combined with lncRNAs Predicts the Prognosis and Immune Microenvironment of Breast Cancer

Zhang, L., Zhang, Y., Bao, J., Gao, W., Wang, D., & Pan, H. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5422698 · Cited by 14 · see citing works

Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation

Wang, L., Yang, X., Song, Q., Fu, J., Wang, W., Du, K., Chen, S., Cao, J., Huang, R., & Zou, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.617555 · Cited by 14 · see citing works

Identification of a novel prognostic signature for HCC and analysis of costimulatory molecule-related lncRNA AC099850.3

Wang, Q., Fang, Q., Huang, Y., Zhou, J., & Liu, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-13792-z · Cited by 14 · see citing works

Demethylzelasteral inhibits proliferation and EMT via repressing Wnt/β-catenin signaling in esophageal squamous cell carcinoma

Yu, J., Wang, W., Liu, B., Gu, J., Chen, S., Cui, Y., & Sun, G. (2021) · Journal of Cancer · doi:10.7150/jca.45493 · Cited by 14 · see citing works

Predicting drug responses of unseen cell types through transfer learning with foundation models

Wang, Y., Liu, X., Fan, Y., Xie, B., Cheng, J. S.-C., Wong, K. C., Cheung, P. P., King, I., & Li, Y. (2025) · Nature Computational Science · doi:10.1038/s43588-025-00887-6 · Cited by 14 · see citing works

Integrating artificial intelligence in osteosarcoma prognosis: the prognostic significance of SERPINE2 and CPT1B biomarkers

Qu, H., Jiang, J., Zhan, X., Liang, Y., Guo, Q., Liu, P., Lü, L., Yang, Y., Xu, W., Zhang, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54222-6 · Cited by 13 · see citing works

Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents

Liang, C., Zhou, Y., Xin, L., Kang, K., Tian, L., Zhang, D., Li, H., Zhao, Q., Gao, H., & Shi, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116504 · Cited by 13 · see citing works

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer

Ferrari, P., Schiavone, M. L., Scatena, C., & Nicolini, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073438 · Cited by 13 · see citing works

A novel strategy for designing the magic shotguns for distantly related target pairs

Luo, Y., Wang, P., Mou, M., Zheng, H., Hong, J., Tao, L., & Zhu, F. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac621 · Cited by 12 · see citing works

Innovating Cancer Treatment Through Cell Cycle, Telomerase, Angiogenesis, and Metastasis

Yousefi, T., Jobani, B. M., Taebi, R., & Qujeq, D. (2024) · DNA and Cell Biology · doi:10.1089/dna.2024.0109 · Cited by 12 · see citing works

Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor–positive mammary carcinogenesis

Buqué, A., Bloy, N., Petroni, G., Jiménez‐Cortegana, C., Sato, A., Iribarren, C., Yamazaki, T., Galassi, C., Hensler, M., Bhinder, B., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae329 · Cited by 12 · see citing works

After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer

Teysir, J., Lloyd, M. R., Alkassis, S., Callahan, R. D., Fairley, R., Wander, S. A., Bardia, A., & Jhaveri, K. L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473372 · Cited by 12 · see citing works

Polysaccharides from Hemerocallis citrina Baroni Inhibit the Growth of Hepatocellular Carcinoma Cells by Regulating the Wnt/β-Catenin Pathway

Sang, T., Fu, Y. J., & Song, L. J. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2216915 · Cited by 11 · see citing works

Double-Faced Immunological Effects of CDK4/6 Inhibitors on Cancer Treatment: Challenges and Perspectives

Liu, Y., Deng, Y., Yang, C., & Naranmandura, H. (2024) · Bioengineering · doi:10.3390/bioengineering11111084 · Cited by 11 · see citing works

Rationally designed Pyrazolo[1,5-a]pyrimidines as dual inhibitors of CA IX/XII and CDK6: A novel approach for NSCLC treatment

Elkotamy, M. S., Elkelesh, I. A., Giovannuzzi, S., Ismail, R. S. M., El-Refaie, W. M., Almehizia, A. A., Naglah, A. M., Nocentini, A., Supuran, C. T., Farès, M., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117752 · Cited by 11 · see citing works

Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma

Wang, Z., Zhou, G., Cao, R., Zhang, G., Zhang, Y., Xiao, M., Liu, L., & Zhang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1592259 · Cited by 11 · see citing works

AMPA Receptor Encephalitis in a Patient With Metastatic Breast Cancer Receiving Palbociclib

Matthews, E., Schmitt, B. L., Passeri, M., Mizenko, C., Orjuela, K. D., & Piquet, A. L. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200012 · Cited by 11 · see citing works

Network analysis reveals miRNA crosstalk between periodontitis and oral squamous cell carcinoma

Li, Z., Fu, R., Wen, X., & Zhang, L. (2023) · BMC Oral Health · doi:10.1186/s12903-022-02704-2 · Cited by 11 · see citing works

Comprehensive Analysis of Cell Cycle-Related Genes in Patients With Prostate Cancer

Liu, Z., Pan, R., Li, W., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.796795 · Cited by 10 · see citing works

Novel 3-Methyleneisoindolinones Diversified via Intramolecular Heck Cyclization Induce Oxidative Stress, Decrease Mitochondrial Membrane Potential, Disrupt Cell Cycle, and Induce Apoptosis in Head and Neck Squamous Cell Carcinoma Cells

Sharma, A., Anand, P., Padwad, Y. S., & Maurya, S. K. (2022) · ACS Omega · doi:10.1021/acsomega.2c05378 · Cited by 10 · see citing works

Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response

Tang, C., Corredeira, P., Casimiro, S., Shi, Q. F., Han, Q., Sukdao, W., Cavaco, A. C. M., Melo-Alvim, C., Matos, C. O., Abreu, C. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61685-2 · Cited by 9 · see citing works

Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

Tarrado‐Castellarnau, M., Foguet, C., Tarragó‐Celada, J., Palobart, M., Hernández-Carro, C., Perarnau, J., Zodda, E., Polat, I. H., Marín, S., Suárez‐Bonnet, A., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03495-w · Cited by 12 · see citing works

Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review

Zheng, S., Chen, Y., Zhu, Z., Li, N., He, C., Koeffler, H. P., Han, X., Wei, Q., & Xu, L. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500021 · Cited by 9 · see citing works

ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma

Wang, Y., Zhang, Y., Mi, J., Jiang, C., Wang, Q., Li, X., Zhao, M., Geng, Z., Song, X., Li, J., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02380-0 · Cited by 9 · see citing works

Integrated Bioinformatics and Experimental Analysis Identified TRIM28 a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Liver Hepatocellular Carcinoma

Han, J., Wang, Y., Zhou, H., Ai, S., & Wan, D. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/6267851 · Cited by 9 · see citing works

nc‐RNA‐mediated high expression of CDK6 correlates with poor prognosis and immune infiltration in pancreatic cancer

Zhao, Y., Xu, B., Wang, F., Jiang, F., Xu, J., & Yu, D. (2022) · Cancer Medicine · doi:10.1002/cam4.5260 · Cited by 9 · see citing works

MPA/DMBA-driven mammary carcinomas

Buqué, A., Pérez-Lanzón, M., Petroni, G., Humeau, J. F., Bloy, N., Yamazaki, T., Sato, A., Kroemer, G., & Galluzzi, L. (2020) · Methods in cell biology · doi:10.1016/bs.mcb.2020.08.003 · Cited by 10 · see citing works

Senescence Inflames the Pancreatic Tumor Microenvironment

Petroni, G., & Galluzzi, L. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100020 · Cited by 9 · see citing works

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers

Chai, A. W. Y., Yee, P. S., & Cheong, S. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837835 · Cited by 8 · see citing works

Immune‐related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia

Xu, Q., Cao, D., Fang, B., Yan, S., Hu, Y., & Guo, T. (2022) · Cancer Medicine · doi:10.1002/cam4.4687 · Cited by 8 · see citing works

Hybrid control of Turing instability and Hopf bifurcation in CDK1-APC feedback systems with diffusion

Luan, Y., Xiao, M., Wang, Z., & Zhao, J. (2023) · Journal of the Franklin Institute · doi:10.1016/j.jfranklin.2023.09.036 · Cited by 8 · see citing works

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma

Chen, Y., Jin, Y., Chen, Y.-K., Cui, C., Yao, J., Zhang, Y., Li, M. H., Cao, G. F., Yang, S., Fan, Y. H., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.005 · Cited by 6 · see citing works

Assessment of transcription inhibition as a characteristic of immunogenic cell death

Cerrato, G., Humeau, J. F., Sauvat, A., Kepp, O., & Kroemer, G. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.12.026 · Cited by 6 · see citing works

Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2− breast cancer

Li, S., Zhang, X., & Pang, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113059 · Cited by 5 · see citing works

Assessment of type I interferon responses as a feature of immunogenic cell death

Forveille, S., Sauvat, A., Zhang, S., Zhao, L., Kroemer, G., & Kepp, O. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.12.028 · Cited by 5 · see citing works

Circular RNA ERBIN Promotes Proliferation of Hepatocellular Carcinoma via the miR-1263/CDK6 Axis

Yang, S., Yu, F., Ji, Y., Shen, Y., Lu, H., Gao, Y., Zhang, F., Wang, X., & Zhang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878513 · Cited by 5 · see citing works

A novel immune-related gene signature correlated with serum IL33 expression in acute myeloid leukemia prognosis.

Xie, J., Wang, W., Wang, N., Dong, Q., Han, H., Feng, Y.-P., Yuan, Y., Feng, J., & Chen, K. (2023) · PubMed Central · Cited by 5 · see citing works

A Novel Scoring Model of Deubiquitination Patterns Predicts Prognosis and Immunotherapeutic Response in Hepatocellular Carcinoma

Zhang, J., Wu, G., Peng, R., Cao, J., Tu, D., Zhou, J., Su, B., Jin, S., Jiang, G., Zhang, C., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101789 · Cited by 5 · see citing works

Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine

Qureshi, M. A., Khan, M. Y., Imran, A., Maqsood, Q., Hussain, N., & Ali, S. W. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_254 · Cited by 5 · see citing works

Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1β Secretion and T Cell Adjuvanticity

Weiss, A. M., López, M. A., Rosenberger, M. G., Kim, J. Y., Shen, J., Chen, Q., Ung, T. W.-M., Ibeh, U., Knight, H. R., Rutledge, N. S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00516 · Cited by 4 · see citing works

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Pernas, S., Sanfeliu, E., Villacampa, G. J., Salvador, J., Perelló, A., González, X., Jiménez, B., Merino, M. J., Palacios, P., Pascual, T., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00710-x · Cited by 5 · see citing works

A N-(4-chlorophenyl)-γ-amino acid derivatives exerts in vitro anticancer activity on non-small cell lung carcinoma cells and enhances citosine arabinoside (AraC)-induced cell death via mitochondria-targeted pathway

Kavaliauskas, P., Žukauskas, Š., Anusevičius, K., Balandis, B., Vaickelionienė, R., Petraitis, V., & Mickevičius, V. (2021) · Results in Chemistry · doi:10.1016/j.rechem.2021.100193 · Cited by 5 · see citing works

Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies

Safaroghli‐Azar, A., Emadi, F., Lenjisa, J. L., Mekonnen, L. B., & Wang, S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103525 · Cited by 5 · see citing works

Breast Cancer Immunity: It is TIME for the Next ChapterPreprint

Quail, D. F., Park, M., Welm, A. L., & Ekiz, H. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041324 · Cited by 6 · see citing works

CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2− breast cancer

Li, S., Gong, Y., Li, H., Liu, S., Yin, Y., Yu, Y., Chu, Y., Hou, J., Liu, J., Zhang, H., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03786-w · Cited by 4 · see citing works

MicroRNA-486: a dual-function biomarker for diagnosis and tumor immune microenvironment characterization in non-small cell lung cancer

Yu, J., Shen, Y., Xu, Y., Feng, Z., Shen, Y., Zhu, Y., Huan, J., & Peng, Q. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02158-9 · Cited by 4 · see citing works

KMT 2 A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Brock, L., Benzien, L., Lange, S., Hühns, M., Runge, A., Roolf, C., Sekora, A., Knuebel, G., Escobar, H. M., Junghanß, C., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13792 · Cited by 3 · see citing works

Contributions of marine invertebrates to our understanding of human health and disease

Hamdoun, A. M., DeTomaso, A. W., & Foltz, K. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95227-9.00015-4 · Cited by 3 · see citing works

Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma

Wang, Y., Wang, H., & Wang, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2830 · Cited by 3 · see citing works

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors

Saavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández-Abad, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E. M., Chamorro, J., et al. (2023) · Cancers · doi:10.3390/cancers15072000 · Cited by 3 · see citing works

Immunomodulatory effects of CDK4/6 inhibitors

Zhang, S., Xu, Q., Sun, W., Zhou, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188912 · Cited by 34 · see citing works

To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity

Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 59 · see citing works

Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation

Bonelli, M. A., Monica, S. L., Fumarola, C., & Alfieri, R. R. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113676 · Cited by 102 · see citing works

Emerging immunomodulatory effects of CDK4/6 inhibitors in breast cancer therapy: A comprehensive review

Zhang, Y., Chen, B., Lin, S., Zhang, R., Wu, J., & Chen, C. (2025) · Tumor Discovery · doi:10.36922/td025190037 · Cited by 2 · see citing works

Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment

Pandey, P., Khan, F., Upadhyay, T. K., & Sharangi, A. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032236 · Cited by 23 · see citing works